Background: Early diagnosis and the improvement in the treatment options in cancer patients can prolong the survival in the majority of malignancies, although they add no benefit to the survival of patients with non-small cell lung cancer (NSCLC). Some patients with NSCLC respond to the treatment well while others do not. Therefore, new prognostic factors and biomarkers other than the stage of disease should be explored in NSCLC. The management of NSCLC may be different according to those biomarkers. The new biomarkers may help to the clinicians to identify who patients have poor prognosis and respond to the specific treatment. Method: The aim of this study is to investigate whether there is a relationship between the response to treatment and serum level of active EGFR or not. Thirty-three patients with locally advanced, metastatic or recurrent non-small cell lung cancer were enrolled into this study. Cisplatin docetaxel treatment was planned for those patients. Baseline and at the end of second and forth cycle of the treatment, serum EGFR were measured. Patients were divided into 2 groups according to their response to the treatment.SPSS7.0 was used to analyse patient data. Student t test and Mann-Withney U tests were used for the comparison between the groups' averages. Spearmann rho and Ki square tests were used to evaluate the relationships between parameters. Kaplan-Meier method was used for the survival analysis. Result: Of 33 patients, 4 were female and 29 were male. The average of age of patients was 52. 12 patients were stage III, 21 were relapsed or stage IV. Objective response rate and overall response rate were found 15.6%, 34.4% respectively. Progression occurred 34.4% among patients in the study. When serum EGFR level cut off is 0.080 fmol/ml, while in patients who didn't respond, the positivity of serum EGFR level was 55.6%, it was 80% in patients who responded. Baseline serum EGFR levels were higher in patients with stage III disease compared to those of patients with relapsed and stage IV disease. In patients who responded to the therapy, baseline serum EGFR levels were found higher than those of the patients who didn't respond regardless of the stage. Following two cycles of treatment, if serum EGFR level is found high, then the probability to respond to the treatment increases significantly. Conclusion: In conclusion, the serum level of EGFR seems to be a useful biomarker for predicting and monitoring the response to the treatment in patients with NSCLC.
Background: Early diagnosis and the improvement in the treatment options in cancer patients can prolong the survival in the majority of malignancies, although they add no benefit to the survival of patients with non-small cell lung cancer (NSCLC) . Some patients with NSCLC respond to the treatment well while others do not. Therefore, new prognostic factors and biomarkers other than the stage of disease should be explored in NSCLC. The management of NSCLC may be different according to those biomarkers. The new biomarkers may help to the clinicians to identify who patients have poor prognosis and respond to the specific treatment. Method: The aim of this study is to investigate whether there is a relationship between the response to treatment and serum level of active EGFR or not. Thirty-three patients with locally advanced, metastatic or recurrent non-small cell lung cancer were enrolled into this study. Cisplatin docetaxel treatment was planned for those patients. Baseline and at the end of second and forth cycle of the treatment, serum EGFR were measured. Patients were divided into 2 groups according to their response to the treatment.SPSS7.0 was used to analyse patient data. Student t test and Mann-Withney U tests were used for the comparison between the groups' averages. Spearmann rho and Ki square tests were used to evaluate the relationships between parameters. Kaplan-Meier method was used for the survival analysis. Result: Of 33 patients, 4 were female and 29 were male. The average of age of patients was 52. 12 patients were stage III, 21 were relapsed or stage IV. Objective response rate and overall response rate were found 15.6%, 34.4% respectively. Progression occurred 34.4% among patients in the study. When serum EGFR level cut off is 0.080 fmol/ml, while in patients who didn't respond, the positivity of serum EGFR level was 55.6%, it was 80% in patients who responded. Baseline serum EGFR levels were higher in patients with stage III disease compared to those of patients with relapsed and stage IV disease. In patients who responded to the therapy, baseline serum EGFR levels were found higher than those of the patients who didn't respond regardless of the stage. Following two cycles of treatment, if serum EGFR level is found high, then the probability to respond to the treatment increases significantly. Conclusion: In conclusion, the serum level of EGFR seems to be a useful biomarker for predicting and monitoring the response to the treatment in patients with NSCLC. A total of 423 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of SMO mutation and other genes were detected by next generation sequencing. Result: SMO gene mutation rate was 2.60% (11/423) in non-small cell lung cancer, including T179M (4 patients), S566R (1 patient), P694Lfs*82 (1 patient), S590T (1 patient), P693S (1 patient), P60L (1 patient), E211D plus G212C (1 patient) and M230I plus A289T (1 patient), and median overall survival (OS) for these patients was 24.0 months. Among them, all patients were SMO gene with co-occurring mutation. Briefly, patients with (n¼6) or without (n¼5) co-occurring EGFR mutations had a median OS of 19.0 months and 25.0 months respectively (P¼0.23); patients with (n¼2) or without (n¼9) co-occurring TP53 mutations had a median OS of 19.0 months and 25.0 months respectively (P¼0.36); patients with (n¼3) or without (n¼8) co-occurring KRAS mutations had a median OS of 23.0 months and 24.0 months respectively (P¼0.75); patients with (n¼4) or without (n¼7) co-occurring BRCA2 mutations had a median OS of 16.0 months and 24.0 months respectively (P¼0.01). Conclusion: SMO mutations may be a potential novel mechanism of acquired resistance in EGFR-mutated NSCLC patients. Background: Detection of genomic aberrations in cell-free DNA (cfDNA), requiring ultra-deep sequencing due to the low allelic frequencies (AF) of mutation, has been utilized to monitor treatment response. However, 20%-30% of patients yield no mutation from plasma genotyping despite deep sequencing depth, thus necessitating alternative monitoring method. The role of aberrant DNA methylation in the process of tumorigenesis both at individual genes and a genomewide scale has been well elucidated. We investigated the potential of DNA methylation as a biomarker for treatment monitoring. Method:
We investigated the performance of mutation and DNA methylation as biomarkers to evaluate response to osimertinib using a DNA methylation panel consisting of 100,000 CpG sites and a targeted panel for mutation detection consisting of 168 lung cancer related genes with an average sequencing depth of 1,000x and 10,000x, respectively. Longitudinal plasma samples from 6 patients undergoing osimertinib were collected prior to treatment and at regular interval until disease progression, ranged from 6 to 9 times. Methylation level of a given sample was reflected by the percentage of significantly methylated blocks, which were significantly hypermethylated blocks comparing to healthy individuals. Result: All patients had EGFR sensitizing mutation and T790M at baseline. Four patients had additional concurrent mutations, including TP53, RB1, OR6F1 and BRCA2. At PD, all patients had detectable mutations except for one and 3 developed EFGR C797S. Four patients had at least two times of no detectable mutation during treatment. Among them, P05 and P06 had 5 and 6 times of no detectable mutation, respectively. In contrast, all patients had significantly methylated blocks detected at every point. In general, the trend of changes in mutation AF corresponds to the changes in the percentage of significantly methylated blocks in all patients except for one, who only had mutations detected at baseline and had consistently detectable DNA methylation at every point. Collectively, DNA
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